Drug-Discovery

Kuano is a Cambridge-based startup applying quantum computing to drug discovery and molecular simulation using proprietary quantum algorithms. The company develops quantum software solutions that enable pharmaceutical and biotech companies to accelerate drug development through more accurate molecular modeling. Kuano’s quantum algorithms target specific challenges in computational drug discovery where quantum computers can provide advantages over classical simulation methods, particularly for complex molecular systems.

2025 Developments: The company continues to enhance its quantum software platform and developer tools in 2025. Focus remains on improving algorithm efficiency and expanding use case applications. Active engagement with the quantum developer community drives product evolution.

Kuano uses quantum simulation and quantum-inspired AI for enzyme drug design with programs in epigenetics, protein degradation, and infectious disease. The London company develops quantum-enhanced drug discovery platforms. Kuano combines quantum algorithms with machine learning to accelerate enzyme engineering and drug design, targeting challenging therapeutic areas where conventional computational methods provide limited insights.

2025 Developments: The company continues its quantum technology initiatives throughout 2025. Focus remains on advancing core technologies and expanding market presence. Ongoing development activities position the company for future growth in the quantum industry.

Molecular Quantum Solutions (MQS) is a German quantum chemistry startup that raised €600K pre-seed funding in 2023 to convert its tool stack into SaaS for pharmaceutical and chemical industries. The company develops quantum simulation software for molecular modeling and materials design applications. MQS targets chemists and materials scientists with user-friendly quantum software that abstracts the complexity of quantum computing, enabling domain experts to leverage quantum algorithms for computational chemistry without quantum computing expertise.

Novartis AG is a Swiss multinational pharmaceutical corporation founded in 1996 (through merger of Ciba-Geigy and Sandoz), headquartered in Basel, Switzerland. Novartis explores quantum computing applications for drug discovery including molecular simulation, protein folding, drug-target interaction modeling, and pharmaceutical development. The company collaborates with quantum computing providers and quantum software companies developing quantum algorithms for computational drug discovery. Novartis investigates quantum machine learning for analyzing pharmaceutical data and quantum simulation for understanding complex biological molecules. The company serves global pharmaceutical industry requiring quantum-enhanced computational capabilities for drug discovery and development. Novartis advances quantum computing applications in pharmaceutical research demonstrating practical quantum applications for healthcare and drug discovery accelerating pharmaceutical development through quantum technology and quantum-enhanced computational chemistry.

ProteinQure is a Toronto biotech company combining quantum computing, machine learning, and molecular simulations to accelerate protein-based therapy design. The company uses quantum algorithms and AI to navigate the vast space of possible protein structures and sequences to identify therapeutic candidates. ProteinQure’s technology platform addresses the complexity of protein engineering for drug development, potentially enabling the design of novel biologics and protein therapeutics with improved properties and reduced development timelines.

Qunova Computing is an emerging quantum computing company focused on drug discovery applications using quantum simulation techniques. The company develops quantum algorithms and software for pharmaceutical research, targeting molecular simulation and drug design challenges. While maintaining a relatively low public profile, Qunova represents the growing ecosystem of specialized quantum software companies focused on high-value applications in life sciences and drug development.

2025 Developments: The company continues to enhance its quantum software platform and developer tools in 2025. Focus remains on improving algorithm efficiency and expanding use case applications. Active engagement with the quantum developer community drives product evolution.